Skip to Main Content

Author Details

Teresa Helsten
Moores Cancer Center, University of California San Diego
2006
27
18
PMIDPaper TitleJournal TitlePublished Year
37475168Association of physician burnout with perceived EHR work stress and potentially actionable factors.J Am Med Inform Assoc2023
37184539Development, Usability Testing, and Implementation Assessment of Cancer Related Infertility Score Predictor, an Online Cancer Related Infertility Risk Counseling Tool.J Adolesc Young Adult Oncol2023
35223458Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.Front Oncol2022
33470879Theory-Guided Development of Fertility Care Implementation Strategies for Adolescent and Young Adult Cancer Survivors.J Adolesc Young Adult Oncol2021
34529000Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.JAMA Oncol2021
34611148Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ Breast Cancer2021
34741023Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.Nat Commun2021
34131001Relevance of Platinum-free Interval and <i>BRCA</i> Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g<i>BRCA</i> Advanced Breast Cancer (BROCADE3 Crossover).Clin Cancer Res2021
34143979Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell2021
32701140Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.JAMA Oncol2020
32031889MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.J Clin Oncol2020
32053137Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.JAMA Oncol2020
30926636Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.Mol Cancer Ther2019
30442736Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2018
26873727Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.Mol Cancer Ther2016
26373574The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res2016
27196769Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics.Mol Cancer Ther2016
27406346Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med2016
25950492Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.Cell Cycle2015
26247885Genomic landscape of salivary gland tumors.Oncotarget2015
26243651Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.J Oncol Pract2015
26418953Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.Oncotarget2015
26224133Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.Cancer Metastasis Rev2015
24942463Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.J Neurooncol2014
21388255Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer.J Palliat Med2011
18508915Differences in regulation of Drosophila and vertebrate integrin affinity by talin.Mol Biol Cell2008
16371365Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity.J Biol Chem2006
  • 1 - 27 of 27

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 2
Eric C Polley
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 4
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 4
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 0
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 2
Nikhil Wagle
Dana-Farber Cancer Institute
Career Start Year 2000
Number of shared co-authors 2
Liewei Wang
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 2
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 1
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 3
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 0
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 0
Yi-Mi Wu
University of Michigan Medical School ann arbor
Career Start Year 1995
Number of shared co-authors 0
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 6
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 2
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 3
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 5
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 3
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 1
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 6
Katherine Stemke-Hale
MD Anderson Cancer Center, University of Texas
Career Start Year 1989
Number of shared co-authors 0
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 3
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 3

Collaborators

Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Co-authored papers 13
Christina Yau
University of California San Francisco
Co-authored papers 8
Rita Nanda
Co-authored papers 8
Laura J Van't Veer
University of California San Francisco
Co-authored papers 8
Judy C Boughey
Mayo Clinic
Co-authored papers 8
Claudine Isaacs
Co-authored papers 8
William F Symmans
Co-authored papers 8
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 8
Lajos Pusztai
Co-authored papers 6
Scott M Berry
University of Kansas Medical Center
Co-authored papers 6
Melissa Paoloni
Center for Cancer Research, National Cancer Institute
Co-authored papers 5
Minetta C Liu
Co-authored papers 5
Paul T Fanta
University of California San Diego Moores Cancer Center
Co-authored papers 4
Denise M Wolf
University of California San Francisco
Co-authored papers 3
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 3
Rachel L Yung
University of Washington
Co-authored papers 2
Paulette Mhawech-Fauceglia
University of Southern California
Co-authored papers 2
Scott M Lippman
Moores Cancer Center, university of california san diego
Co-authored papers 2
Brian M Feldman
Co-authored papers 2
Thomas J Savides
University of California San Diego
Co-authored papers 1
Erin Gross
university of california san diego Health
Co-authored papers 1
Rebecca Rosen
university of california san diego School of Medicine
Co-authored papers 1
Judy E Garber
Dana-Farber Cancer Institute
Co-authored papers 1
Matthew P Goetz
Mayo Clinic
Co-authored papers 1
Sidney Zisook
VA San Diego Healthcare System San Diego California.
Co-authored papers 1
Sally L Baxter
University of California San Diego
Co-authored papers 1
Vered Stearns
Co-authored papers 1
Bob S Carter
Massachusetts General Hospital and Harvard Medical School
Co-authored papers 1
David Maag
Co-authored papers 1
Ossama Tawfik
University of Kansas
Co-authored papers 1
Release 1.2